top of page

Revolutionizing Diabetic Retinopathy Screening with AEYE Health's FDA-Cleared AI Solution

Tackling the Diabetic Retinopathy Problem


Diabetic retinopathy (DR) is a common complication of diabetes, affecting millions of people worldwide. In the United States alone, over 35 million people with diabetes are at risk of developing this condition. Globally, more than 422 million people with diabetes are vulnerable to diabetic retinopathy, making it a significant public health concern. It is the leading cause of blindness among the working-age population, with an estimated 85% of patients with diabetes over the age of 40 developing this condition. Early detection and treatment are crucial in preventing vision loss, but unfortunately, many people with diabetes are unable to obtain annual eye exams, leaving them at risk for this potentially devastating complication.


The Global Impact of Diabetic Retinopathy: A Growing Epidemic


The prevalence of diabetes and its associated complications, including diabetic retinopathy, has been steadily increasing worldwide. The International Diabetes Federation estimates that by 2045, the number of people with diabetes will reach 700 million, further highlighting the urgent need for effective screening and treatment strategies. The World Health Organization (WHO) recognizes diabetic retinopathy as a significant cause of avoidable blindness.. As the global diabetes epidemic continues to grow, addressing the challenge of diabetic retinopathy becomes increasingly critical.


The Current State of Diabetic Retinopathy Screening: Limitations and Challenges


Traditional diabetic retinopathy screening methods rely on expensive specialist screenings, which are often inaccessible to many patients. Furthermore, adherence to annual eye exams is generally low, with only 15-50% of individuals completing their recommended annual exam. As a result, many cases of diabetic retinopathy go undetected, leading to irreversible damage and vision loss. In the United States, more than 90% of vision loss caused by diabetic retinopathy can be avoided with early detection and treatment. However, the vast majority of people with diabetes in the US find themselves unable to obtain annual eye exams, exacerbating the problem.

Healthcare systems face several challenges in providing adequate diabetic retinopathy screening to patients, including:

  • High costs: Specialist eye exams can be expensive, and not all insurance plans cover the full cost of diabetic retinopathy screening, creating a financial barrier for many patients.

  • Inconvenience: The need to schedule separate appointments with eye care specialists and primary care providers can be time-consuming and inconvenient, leading to lower adherence rates.

  • Inadequate Knowledge: Studies have revealed that a significant number of patients fail to adhere to diabetic retinopathy screening protocols primarily due to insufficient knowledge and awareness of the condition.

  • Limited availability of trained eye care professionals: A shortage of ophthalmologists and optometrists, particularly in rural and underserved areas, makes it difficult for patients to access timely eye exams.

AEYE Health's FDA-Cleared AI Solution: A Game Changer for Diabetic Retinopathy Screening


AEYE Health has developed an innovative AI-based diagnostic screening system for diabetic retinopathy, which recently received FDA clearance. This groundbreaking solution offers several advantages over traditional screening methods:

  • Best-in-class clinical efficacy: With 93% sensitivity and 91.4% specificity, AEYE Health's AI solution boasts exceptional clinical efficacy in detecting diabetic retinopathy.

  • One image per eye: Unlike other diagnostic systems, AEYE Health's AI requires only a single image per eye, streamlining the screening process and reducing screening time to under 2 minutes, making it more practical and efficient.

  • High imageability: The system delivers diagnostic results for over 99% of patients, and rarely requires dilation.

  • Affordability: By offering screening at the point of care, the financial strain on patients is significantly reduced. This approach ensures that patients are referred to retinal specialists only if the condition is detected, leading to savings in both time and money.

The Impact of AEYE-DS on Primary Care and Healthcare Accessibility


By incorporating AEYE Health's FDA-cleared AI solution into primary care settings, healthcare providers can offer diabetic retinopathy screening at the patient's point of care, eliminating the need for costly specialist examinations. This accessibility can lead to:

  • Improved patient outcomes: Early detection and treatment of diabetic retinopathy can significantly reduce the risk of vision loss and prevent irreversible complications.

  • Increased convenience: Patients can receive screening during their regular primary care visits, eliminating the need for additional appointments with specialists.

  • Greater adherence: With easier access to screening, more patients are likely to complete their annual eye exams, leading to better disease management.

The Role of Reimbursement and CPT Code 92229 in Facilitating AI-Diagnostic Screening


The recent approval of CPT code 92229 for AI-diagnostic screening of diabetic retinopathy in the United States is a significant step in facilitating the adoption of AI-based diagnostics in clinical practice. This new code makes AI-based screening reimbursable, removing a significant financial barrier and encouraging healthcare providers to adopt this innovative technology.


Future Goals for AEYE Health: Expanding the Reach of AI-Based Diagnostics


AEYE Health continues to innovate and expand its AI-based diagnostic solutions. The company is working on receiving clearance for the first diagnostic screening solution for a portable camera, following promising pivotal study data. Additionally, AEYE Health is developing a comprehensive screening platform for the detection of both ocular and systemic conditions.


Leading the Way in AI-Based Diagnostics for Ophthalmology


AEYE Health's FDA-cleared AI solution for diabetic retinopathy screening is a significant milestone in the field of ophthalmology and diabetes care. By offering a practical and accurate screening alternative, AEYE Health is revolutionizing the way diabetic retinopathy is detected and managed. As the global diabetes epidemic continues to grow, AI-based solutions like AEYE's diagnostic screening system will play an increasingly important role in addressing the challenge of diabetic retinopathy and transforming the landscape of ophthalmology for the better.




Comments


  • https://www.linkedin.com/company/aeyehealth/
  • https://www.facebook.com/aeyehealth/
  • https://twitter.com/aeyehealth
Hero Section2 (2).png
footer2.png

Get the Latest News

Stay informed by signing up with the latest news and insights from Aeye Health

Thanks for submitting!

bottom of page